相似文献
1
Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.
Cancer Cell. 2016 May 9;29(5):723-736. doi: 10.1016/j.ccell.2016.04.002.
2
Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
J Clin Endocrinol Metab. 2018 Dec 1;103(12):4511-4523. doi: 10.1210/jc.2018-01348.
3
Integrated genomic characterization of adrenocortical carcinoma.
Nat Genet. 2014 Jun;46(6):607-12. doi: 10.1038/ng.2953. Epub 2014 Apr 20.
4
Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples.
Nucleic Acids Res. 2015 Oct 30;43(19):9327-39. doi: 10.1093/nar/gkv908. Epub 2015 Oct 7.
5
Targeted Assessment of Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma.
Clin Cancer Res. 2019 Jun 1;25(11):3276-3288. doi: 10.1158/1078-0432.CCR-18-2693. Epub 2019 Feb 15.
6
Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape.
BMC Med Genomics. 2020 Nov 4;13(1):165. doi: 10.1186/s12920-020-00809-7.
7
microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Oncologist. 2019 Jun;24(6):e241-e250. doi: 10.1634/theoncologist.2018-0849. Epub 2019 Mar 27.
8
Detailed genomic characterization identifies high heterogeneity and histotype-specific genomic profiles in adrenocortical carcinomas.
Mod Pathol. 2018 Aug;31(8):1257-1269. doi: 10.1038/s41379-018-0042-6. Epub 2018 Mar 26.
9
TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
Int J Mol Med. 2018 Sep;42(3):1675-1683. doi: 10.3892/ijmm.2018.3735. Epub 2018 Jun 20.
10
Development and Validation of an m6A RNA Methylation Regulators-Based Signature for Predicting the Prognosis of Adrenocortical Carcinoma.
Front Endocrinol (Lausanne). 2021 Feb 22;12:568397. doi: 10.3389/fendo.2021.568397. eCollection 2021.
引用本文的文献
1
Hyperandrogenism-induced Athletic Excellence in a Young Patient with Adrenocortical Carcinoma: 10 Years of Remission.
JCEM Case Rep. 2025 Jul 31;3(9):luaf170. doi: 10.1210/jcemcr/luaf170. eCollection 2025 Sep.
2
β-catenin functions as a molecular adapter for disordered cBAF interactions.
Mol Cell. 2025 Jul 15. doi: 10.1016/j.molcel.2025.06.026.
3
Bimodal Genomic Approach Predicting Semaphorin 7A (SEMA7A) as Prognostic Biomarker in Adrenocortical Carcinoma.
Cancers (Basel). 2025 Jun 21;17(13):2078. doi: 10.3390/cancers17132078.
4
WMRCA + : a weighted majority rule-based clustering method for cancer subtype prediction using metabolic gene sets.
Hereditas. 2025 Jul 7;162(1):121. doi: 10.1186/s41065-025-00487-4.
5
Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma.
Nat Commun. 2025 Jul 1;16(1):5511. doi: 10.1038/s41467-025-60649-w.
6
The Efficacy and Safety of Multi-Kinase Inhibitors in Adrenocortical Carcinoma: A Systematic Review and Single-Arm Meta-Analysis.
Cancers (Basel). 2025 Jun 16;17(12):2004. doi: 10.3390/cancers17122004.
7
Apoptosis-inducing factor (AIF) at the crossroad of cell survival and cell death: implications for cancer and mitochondrial diseases.
Cell Commun Signal. 2025 Jun 4;23(1):264. doi: 10.1186/s12964-025-02272-2.
8
HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib.
ESMO Open. 2025 May 19;10(6):105060. doi: 10.1016/j.esmoop.2025.105060.
9
Editorial: Adrenocortical carcinoma: advancing treatment beyond surgery for a rare disease.
Front Endocrinol (Lausanne). 2025 Apr 24;16:1589785. doi: 10.3389/fendo.2025.1589785. eCollection 2025.
10
Identification and validation of susceptibility modules and hub genes of adrenocortical carcinoma through WGCNA and machine learning.
Discov Oncol. 2025 May 3;16(1):663. doi: 10.1007/s12672-025-02396-4.
本文引用的文献
1
Formalin-fixed, paraffin-embedded (FFPE) tissue epigenomics using Infinium HumanMethylation450 BeadChip assays.
Lab Invest. 2015 Jul;95(7):833-42. doi: 10.1038/labinvest.2015.53. Epub 2015 Apr 13.
2
Genomic landscape of paediatric adrenocortical tumours.
Nat Commun. 2015 Mar 6;6:6302. doi: 10.1038/ncomms7302.
3
Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes.
Nat Genet. 2015 Feb;47(2):106-14. doi: 10.1038/ng.3168. Epub 2014 Dec 15.
4
The landscape and therapeutic relevance of cancer-associated transcript fusions.
Oncogene. 2015 Sep 10;34(37):4845-54. doi: 10.1038/onc.2014.406. Epub 2014 Dec 15.
5
Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.
J Clin Endocrinol Metab. 2015 Mar;100(3):E493-502. doi: 10.1210/jc.2014-3282. Epub 2014 Dec 9.
6
PKA catalytic subunit mutations in adrenocortical Cushing's adenoma impair association with the regulatory subunit.
Nat Commun. 2014 Dec 5;5:5680. doi: 10.1038/ncomms6680.
7
BioBloom tools: fast, accurate and memory-efficient host species sequence screening using bloom filters.
Bioinformatics. 2014 Dec 1;30(23):3402-4. doi: 10.1093/bioinformatics/btu558. Epub 2014 Aug 20.
8
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.
Nat Med. 2014 Jun;20(6):682-8. doi: 10.1038/nm.3559. Epub 2014 May 18.
9
The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors.
Endocr Relat Cancer. 2014 May 6;21(3):427-34. doi: 10.1530/ERC-14-0016. Print 2014 Jun.
10
Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins.
Nat Genet. 2014 Jun;46(6):588-94. doi: 10.1038/ng.2981. Epub 2014 May 4.
Zotero 插件